Protocol Ledger

Academic / Institutional Sponsor · Consolidated Sponsor Hub

Icahn School of Medicine at Mount Sinai: Clinical Trials & FDA Approval Profile

Icahn School of Medicine at Mount Sinai (Global / Institutional) sponsors 68 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 37 active protocols (33 recruiting now), 14 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Primary Focus: Oncology and Hematology Interactive Workbench: Open Full Annual Timeline & Compare ->
Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)23.5%
Median Closed Enrollment vs National (145 pts)25 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Icahn School of Medicine at Mount Sinai
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)68
Active Pipeline (Recruiting Now)37 (33)
Completed vs Stopped Early14 / 16 (23.5%)
Median Closed Actual Enrollment25 participants
Physical Hospital Site Disclosure99.5% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Icahn School of Medicine at Mount Sinai
Hospital Research SiteLocationShared Protocols
Mount Sinai Hospital and Icahn School of MedicineNew York, NY59
Emory Winship Cancer InstituteAtlanta, GA4
Cleveland ClinicCleveland, OH3

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by Icahn School of Medicine at Mount Sinai
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT04045665Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABGPhase IIIRECRUITING
NCT05835466Reparixin in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium (MPN-RC 120)Phase IIRECRUITING

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Mount Sinai Health System across sibling Meru public-data platforms.

Explore interactive annual charts and M&A subsidiary rollups in the Icahn School of Medicine at Mount Sinai Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI